Search

Zentalis Pharmaceuticals Inc

Lezárt

2.69 -1.82

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.68

Maximum

2.71

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+225.93% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-44M

287M

Előző nyitás

4.51

Előző zárás

2.69

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 27. 23:51 UTC

Australia's Inflation Rate Expected to Rise to 4.1% Amid Global Economic Pressures Ahead of September 30 Release

2026. szept. 27. 23:51 UTC

China's Non-Manufacturing PMI set for release on September 30, with forecasts indicating continued economic contraction at 49.3 amid cautious market sentiment and geopolitical concerns.

2026. szept. 27. 23:51 UTC

Australia's RBA Trimmed Mean CPI YoY data release on September 30, 2026, is crucial for understanding core inflation trends amid global economic uncertainties and potential interest rate impacts.

2026. szept. 27. 23:51 UTC

Australia's Building Permits Expected to Decline 0.9% in August Amid Mixed Trends and Economic Uncertainty

2026. szept. 27. 23:51 UTC

China's NBS Manufacturing PMI Set for Release on September 30, Forecasted at 50.1 Amid Concerns Over Economic Recovery and Global Trade Relations.

2026. szept. 27. 23:41 UTC

Bank of Japan to Release Key Monetary Policy Minutes Amid Optimism and Inflation Concerns on September 27, 2026

2026. szept. 27. 23:41 UTC

U.S. September 2026 Unemployment Rate Release Forecasts Slight Increase to 4.2%, Amid Cautious Market Sentiment and Economic Policy Discussions

2026. szept. 27. 23:41 UTC

U.S. Average Hourly Earnings Expected to Rise 0.3% in September, Influencing Fed's Rate Hike Decisions Amid Inflation Concerns

2026. szept. 27. 23:41 UTC

U.S. Non-Farm Payrolls Expected to Add 100K Jobs in September Amid Cautious Optimism and Potential Market Volatility

2026. szept. 27. 23:41 UTC

U.S. Labor Force Participation Rate Release on October 2, 2026, Expected Amidst Cautious Sentiment and Economic Challenges

2026. szept. 27. 23:41 UTC

US Average Hourly Earnings Report on October 2 Could Signal Fed Rate Hikes Amid Inflation Concerns and Market Volatility.

2026. szept. 27. 23:11 UTC

S&P Global Manufacturing PMI for South Korea Expected to Show Slight Decline Amid Economic Pressures and Resilient Industries

2026. szept. 27. 23:11 UTC

U.S. Home Prices Expected to Rise 2.2% YoY Amidst Stabilizing Market Sentiment Despite Inflation Pressures

2026. szept. 27. 23:11 UTC

Brazil's Industrial Production MoM Data Release on October 2, 2026: Market Anticipates Recovery Amid Ongoing Volatility.

2026. szept. 27. 23:11 UTC

The EUR/CZK is trading roughly flat at the start of the new week, showing little change since Friday's close and reflecting stable performance.

2026. szept. 27. 23:01 UTC

Correlated Moves
Macro News

The Russell 2000 Index is lower, continuing a decline from Friday's close, amid Boeing's software glitch concerns and ongoing U.S.-China tariff discussions.

2026. szept. 27. 23:01 UTC

Correlated Moves
Macro News

The Nasdaq 100 Index is trading modestly lower amid reports of a U.S.-China tariff agreement on $30 billion in goods and geopolitical concerns.

2026. szept. 27. 23:01 UTC

Macro News

The S&P 500 Index is trading lower amid macroeconomic developments, including the upcoming release of the Bank of Japan's July monetary policy minutes.

2026. szept. 27. 23:01 UTC

Correlated Moves
Macro News

Silver prices fell modestly amid discussions on Iran's military readiness and the upcoming release of the Bank of Japan's policy meeting minutes.

2026. szept. 27. 23:01 UTC

Macro News

The AUD/USD is slightly lower as trading resumes, positioned near the lower end of its one-month range amid upcoming Bank of Japan minutes.

2026. szept. 27. 23:01 UTC

Macro News

Oil (WTI) is advancing modestly as tensions in the Middle East escalate, with Iran signaling a potential disruption to global oil supply routes.

2026. szept. 27. 23:01 UTC

Correlated Moves
Macro News

Gold prices fell modestly, continuing a downward trend as geopolitical tensions and expectations of Bank of Japan minutes weigh on the market.

2026. szept. 27. 23:01 UTC

Correlated Moves
Macro News

Platinum prices are declining, continuing a downward trend influenced by silver's drop and geopolitical tensions affecting global energy markets.

2026. szept. 27. 23:01 UTC

Correlated Moves
Macro News

The Dow Jones Index is lower amid mixed U.S. equities, influenced by U.S.-China tariff discussions and geopolitical concerns over Iran.

2026. szept. 27. 23:01 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% in August, Indicating Strong Business Confidence Amid Economic Uncertainties

2026. szept. 27. 23:01 UTC

U.S. GDP Growth Rate for Q2 2026 Forecasted at 1.6% Amid Positive Foreign Investment and Trade Developments Ahead of September Release.

2026. szept. 27. 23:01 UTC

U.S. GDP Price Index QoQ Final for Q2 2026 set to release on September 30, with a forecasted increase of 0.064%, amid positive market sentiment from U.S.-China trade negotiations aimed at reducing tariffs.

2026. szept. 27. 23:01 UTC

PCE Price Index MoM for August 2026 set to release on September 30, with market expecting a 0.4% increase amid fluctuating inflation trends and rising foreign investment in U.S. equities.

2026. szept. 27. 23:01 UTC

Upcoming PCE Price Index Release on September 30, 2026, May Influence U.S. Inflation Trends and Federal Reserve Policy Amid Mixed Market Sentiment.

2026. szept. 27. 23:01 UTC

Personal Income MoM Data for August 2026 Forecasted to Rise by 0.4%, Indicating Cautious Optimism in U.S. Economic Growth Ahead of Release on September 30.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

225.93% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.8 USD  225.93%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.